A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

This is a first-in-human (FIH), Phase 1 open-label, multicentre dose escalation study investigating AVA6000 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumours that are likely to be FAP positive. The study consists of an initial Phase 1a dose escalation portion and a subsequent Phase 1b dose expansion portion upon completion of the dose escalation portion.

Trial Details

NCT ID
NCT04969835
Phase
PHASE1
Sponsor
Avacta Life Sciences Ltd
Status
RECRUITING
Cancer Type
Salivary Gland Head and Neck Cancer
Interventions
  • AVA6000
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597
  • Houston, Texas, United States|29.76328,-95.36327
  • Seattle, Washington, United States|47.60621,-122.33207
  • Glasgow, United Kingdom|55.86515,-4.25763
  • Leeds, United Kingdom|53.79648,-1.54785

Key Eligibility Criteria

  • The patient has been fully informed about the study and has signed the Informed Consent Form.
  • Male or female patients, ≥ 18 years of age.
  • a) Phase 1a: patients with tumours reported to be FAP positive with histological or cytological confirmation of a locally advanced (unresectable) a…
  • a. salivary gland, urothelial, ovarian, or breast carcinoma, who have either relapsed or progressed on SoC treatment or are intolerant or nonamenab…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Salivary Gland Head and Neck Cancer Trials on Trialify →